Construction of HCC-targeting artificial miRNAs using natural miRNA precursors

Huang,Xiaoming; Jia,Zhenyu

doi:10.3892/etm.2013.1111

Construction of HCC-targeting artificial miRNAs using natural miRNA precursors

Authors:
- Xiaoming Huang
- Zhenyu Jia
View Affiliations

Affiliations: Institute of Hygiene, Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang 310013, P.R. China
Published online on: May 14, 2013 https://doi.org/10.3892/etm.2013.1111
Pages: 209-215

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, particularly in developing countries. Despite the achievements in clinical therapeutics, the HCC mortality rate remains high. A number of artificial microRNA (amiRNA)-based HCC gene therapy studies have demonstrated significant inhibition of invasion and induction of apoptosis of HCC cancer cells, indicating that this type of therapy may be a promising alternative to current therapeutics. Since the structure of the amiRNA precursor in the specific intracellular environment is critical for the processing to mature amiRNA, a precursor structure that may be efficiently processed is desired. In this study, we constructed amiRNAs targeting firefly luciferase with the precursor structures of six HCC-abundant microRNAs: miR-18a, miR-21, miR-192, miR-221, miR-222 and miR-224, and evaluated the processing efficiency of these amiRNAs in the HCC cell lines Hep3B and HepG2 using a luciferase reporter system. The results demonstrated that these amiRNA precursors are capable of being expressed in HCC cells, with the miR-221 precursor‑based amiRNA exhibiting the most efficient inhibition on firefly luciferase at the levels of mRNA and protein activity. This finding provides a basis for constructing HCC-targeting amiRNAs with potent processing efficiency using the precursor structure of miR-221.

View Figures

View References

1.	Mathers C, Fat DM and Boerma J: The global burden of disease: 2004 update. World Health Organization. 2008.
2.	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
3.	Campbell TN and Choy FY: RNA interference: past, present and future. Curr Issues Mol Biol. 7:1–6. 2005.PubMed/NCBI
4.	Sledz CA and Williams BRG: RNA interference in biology and disease. Blood. 106:787–794. 2005. View Article : Google Scholar : PubMed/NCBI
5.	Que XY, Li Y, Han Y and Li XZ: Effects of siRNA-mediated Cdc2 silencing on MG63 cell proliferation and apoptosis. Mol Med Rep. 7:466–470. 2013.PubMed/NCBI
6.	Yin Y, Chen X, Zhang CD, et al: Asymmetric siRNA targeting the bcl-2 gene inhibits the proliferation of cancer cells in vitro and in vivo. Int J Oncol. 42:253–260. 2013.PubMed/NCBI
7.	Boudreau RL, Martins I and Davidson BL: Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol Ther. 17:169–175. 2009. View Article : Google Scholar : PubMed/NCBI
8.	Liu X, Fang H, Chen H, et al: An artificial miRNA against HPSE suppresses melanoma invasion properties, correlating with a down-regulation of chemokines and MAPK phosphorylation. PLoS One. 7:e386592012. View Article : Google Scholar : PubMed/NCBI
9.	Slezak-Prochazka I, Durmus S, Kroesen BJ and van den Berg A: MicroRNAs, macrocontrol: regulation of miRNA processing. RNA. 16:1087–1095. 2010. View Article : Google Scholar : PubMed/NCBI
10.	Starega-Roslan J, Koscianska E, Kozlowski P and Krzyzosiak WJ: The role of the precursor structure in the biogenesis of microRNA. Cell Mol Life Sci. 68:2859–2871. 2011. View Article : Google Scholar : PubMed/NCBI
11.	Zhang KJ, Qian J, Wang SB and Yang Y: Targeting Gene-Viro-Therapy with AFP driving Apoptin gene shows potent antitumor effect in hepatocarcinoma. J Biomed Sci. 19:202012. View Article : Google Scholar : PubMed/NCBI
12.	Zhang KJ, Zhang J, Wu YM, et al: Complete eradication of hepatomas using an oncolytic adenovirus containing AFP promoter controlling E1A and an E1B deletion to drive IL-24 expression. Cancer Gene Ther. 19:619–629. 2012. View Article : Google Scholar : PubMed/NCBI
13.	Han J, Lee Y, Yeom KH, et al: Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. Cell. 125:887–901. 2006. View Article : Google Scholar : PubMed/NCBI
14.	Wang Y, Lee AT, Ma JZ, et al: Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem. 283:13205–13215. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Bala S, Marcos M and Szabo G: Emerging role of microRNAs in liver diseases. World J Gastroenterol. 15:5633–5640. 2009. View Article : Google Scholar : PubMed/NCBI
16.	Boni V, Bandres E, Zarate R, Colucci G, Maiello E and Garcia-Foncillas J: MicroRNAs as a new potential therapeutic opportunity in gastrointestinal cancer. Oncology. 77(Suppl 1): 75–89. 2009. View Article : Google Scholar : PubMed/NCBI
17.	Li M, Li J, Ding X, He M and Cheng SY: microRNA and cancer. AAPS J. 12:309–317. 2010. View Article : Google Scholar
18.	Ishida H, Tatsumi T, Hosui A, et al: Alterations in microRNA expression profile in HCV-infected hepatoma cells: involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway. Biochem Biophys Res Commun. 412:92–97. 2011. View Article : Google Scholar : PubMed/NCBI
19.	Albulescu R, Neagu M, Albulescu L and Tanase C: Tissular and soluble miRNAs for diagnostic and therapy improvement in digestive tract cancers. Expert Rev Mol Diagn. 11:101–120. 2011. View Article : Google Scholar : PubMed/NCBI
20.	Silva JM, Li MZ, Chang K, et al: Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet. 37:1281–1288. 2005.PubMed/NCBI
21.	Xu C, Lee SA and Chen X: RNA interference as therapeutics for hepatocellular carcinoma. Recent Pat Anticancer Drug Discov. 6:106–115. 2011. View Article : Google Scholar : PubMed/NCBI
22.	Borel F, Konstantinova P and Jansen PL: Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol. 56:1371–1383. 2012. View Article : Google Scholar : PubMed/NCBI
23.	Rutella S, Iudicone P, Bonanno G, et al: Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol. Cytotherapy. 14:841–850. 2012. View Article : Google Scholar : PubMed/NCBI
24.	Shojaei F: Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett. 320:130–137. 2012. View Article : Google Scholar : PubMed/NCBI
25.	Zeyaullah M, Patro M, Ahmad I, et al: Oncolytic viruses in the treatment of cancer: a review of current strategies. Pathol Oncol Res. 18:771–781. 2012. View Article : Google Scholar : PubMed/NCBI
26.	Yao N, Yao D, Wang L, et al: Inhibition of autocrine IGF-II on effect of human HepG2 cell proliferation and angiogenesis factor expression. Tumour Biol. 33:1767–1776. 2012. View Article : Google Scholar : PubMed/NCBI
27.	Ibrahim AF, Weirauch U, Thomas M, Grunweller A, Hartmann RK and Aigner A: MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res. 71:5214–5224. 2011. View Article : Google Scholar : PubMed/NCBI
28.	Shi ZM, Wang J, Yan Z, et al: MiR-128 inhibits tumor growth and angiogenesis by targeting p70S6K1. PLoS One. 7:e327092012. View Article : Google Scholar : PubMed/NCBI
29.	Stegmeier F, Hu G, Rickles RJ, Hannon GJ and Elledge SJ: A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci USA. 102:13212–13217. 2005. View Article : Google Scholar : PubMed/NCBI
30.	Chang K, Elledge SJ and Hannon GJ: Lessons from Nature: microRNA-based shRNA libraries. Nat Methods. 3:707–714. 2006. View Article : Google Scholar : PubMed/NCBI
31.	Hinton TM, Wise TG, Cottee PA and Doran TJ: Native microRNA loop sequences can improve short hairpin RNA processing for virus gene silencing in animal cells. J RNAi Gene Silencing. 4:295–301. 2008.PubMed/NCBI
32.	Zeng Y and Cullen BR: Sequence requirements for micro RNA processing and function in human cells. RNA. 9:112–123. 2003. View Article : Google Scholar : PubMed/NCBI
33.	Augello C, Vaira V, Caruso L, et al: MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma. Liver Int. 32:772–782. 2012. View Article : Google Scholar : PubMed/NCBI